X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (499) 499
oncology (415) 415
index medicus (411) 411
chemotherapy (249) 249
female (249) 249
male (237) 237
dacarbazine - analogs & derivatives (218) 218
middle aged (205) 205
aged (189) 189
cancer (188) 188
treatment outcome (172) 172
adult (171) 171
temozolomide (171) 171
melanoma (149) 149
antineoplastic combined chemotherapy protocols - therapeutic use (145) 145
dacarbazine - therapeutic use (144) 144
phase-ii trial (133) 133
care and treatment (125) 125
dacarbazine - administration & dosage (120) 120
metastatic melanoma (119) 119
immunotherapy (117) 117
brain neoplasms - drug therapy (109) 109
radiotherapy (107) 107
antineoplastic agents, alkylating - therapeutic use (106) 106
survival (104) 104
open-label (102) 102
antineoplastic agents - therapeutic use (100) 100
glioblastoma (98) 98
adjuvant temozolomide (97) 97
melanoma - drug therapy (96) 96
prognosis (90) 90
clinical trials (84) 84
glioblastoma - drug therapy (83) 83
disease-free survival (80) 80
metastasis (80) 80
clinical neurology (79) 79
ipilimumab plus dacarbazine (79) 79
aged, 80 and over (76) 76
research (75) 75
combined modality therapy (73) 73
phase-ii (73) 73
trial (73) 73
drug therapy (72) 72
retrospective studies (72) 72
radiation-therapy (71) 71
pharmacology & pharmacy (69) 69
tumors (68) 68
brain neoplasms - therapy (66) 66
malignant glioma (66) 66
double-blind (64) 64
medicine & public health (64) 64
glioblastoma multiforme (63) 63
dacarbazine - adverse effects (62) 62
plus dacarbazine (62) 62
survival analysis (62) 62
brain neoplasms - radiotherapy (61) 61
antineoplastic combined chemotherapy protocols - adverse effects (60) 60
brain neoplasms - mortality (60) 60
analysis (59) 59
bevacizumab (59) 59
ipilimumab (57) 57
therapy (57) 57
melanoma - pathology (56) 56
newly-diagnosed glioblastoma (56) 56
young adult (56) 56
patients (55) 55
dacarbazine (54) 54
glioblastoma - therapy (54) 54
antineoplastic agents (53) 53
cancer therapies (53) 53
cell lung-cancer (53) 53
glioblastoma - mortality (53) 53
survival rate (52) 52
glioblastoma - radiotherapy (51) 51
review (51) 51
skin neoplasms - drug therapy (51) 51
surgery (51) 51
animals (50) 50
antimitotic agents (49) 49
health aspects (49) 49
1st-line treatment (46) 46
adolescent (46) 46
multiforme (46) 46
antibodies, monoclonal - therapeutic use (45) 45
brain neoplasms - pathology (45) 45
nivolumab (43) 43
medical research (42) 42
gliomas (41) 41
hematology (41) 41
skin neoplasms - pathology (41) 41
chemotherapy, adjuvant (40) 40
disease progression (40) 40
glioblastoma - pathology (40) 40
glioma - drug therapy (40) 40
hematology, oncology and palliative medicine (40) 40
medical prognosis (39) 39
toxicity (39) 39
radiotherapy plus concomitant (38) 38
antineoplastic agents, alkylating - adverse effects (37) 37
clinical trials as topic (37) 37
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer, ISSN 0008-543X, 09/2010, Volume 116, Issue 17, pp. 4054 - 4062
Journal Article
Melanoma research, ISSN 0960-8931, 06/2015, Volume 25, Issue 3, pp. 239 - 245
The combined treatment of dacarbazine with an antiangiogenic drug such as bevacizumab may potentiate the therapeutic effects of dacarbazine in metastatic... 
Metastatic Melanoma | Vascular Endothelial Growth Factor | Dacarbazine | Unresectable Melanoma | Combination Therapy | Bevacizumab | MEDICINE, RESEARCH & EXPERIMENTAL | 1ST-LINE TREATMENT | OPEN-LABEL | MALIGNANT-MELANOMA | CANCER | DERMATOLOGY | unresectable melanoma | TRIAL | PLUS DACARBAZINE | STAGE-IV MELANOMA | RANDOMIZED PHASE-2 | ONCOLOGY | metastatic melanoma | vascular endothelial growth factor | bevacizumab | combination therapy | dacarbazine | ENDOTHELIAL GROWTH-FACTOR | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | Skin Neoplasms - drug therapy | Dacarbazine - therapeutic use | Skin - metabolism | Bevacizumab - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Angiogenesis Inhibitors - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Angiogenesis Inhibitors - adverse effects | Skin Neoplasms - pathology | Dacarbazine - administration & dosage | Bevacizumab - administration & dosage | Lymphatic Metastasis | Melanoma - pathology | Melanoma - secondary | Antineoplastic Agents, Alkylating - therapeutic use | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Intention to Treat Analysis | Survival Analysis | Aged | Infusions, Intravenous | Antineoplastic Agents, Alkylating - adverse effects | Drug Monitoring | Skin - drug effects | Index Medicus
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2011, Volume 17, Issue 24, pp. 7732 - 7742
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 09/2017, Volume 146, Issue 3, pp. 531 - 537
Journal Article
The Oncologist, ISSN 1083-7159, 06/2019, Volume 24, Issue 6, pp. 857 - 863
Background Sorafenib and dacarbazine have low single‐agent response rates in metastatic sarcomas. As angiogenesis inhibitors can enhance the efficacy of... 
Soft tissue sarcoma | Angiogenesis | Chemotherapy | Phase II clinical trials | PLACEBO | ADVANCED SOFT-TISSUE | GEMCITABINE PLUS DOCETAXEL | METASTATIC UTERINE LEIOMYOSARCOMA | ONCOLOGY-GROUP | BEVACIZUMAB | DOXORUBICIN | COMBINATION | ONCOLOGY | DOUBLE-BLIND | EUROPEAN-ORGANIZATION
Journal Article
Melanoma Research, ISSN 0960-8931, 2014, Volume 24, Issue 3, pp. 237 - 243
Journal Article
International Journal of Clinical and Experimental Medicine, ISSN 1940-5901, 2016, Volume 9, Issue 12, pp. 23127 - 23133
Cutaneum carcinoma threatens health and lives of patients. Dacarbazine is one of the most important therapeutics for cutaneum carcinoma. Current study was... 
MicroRNA26 | Dacarbazine | Cutaneous squamous cell carcinoma | Colon16 | Apoptosis | INTERLEUKIN-2 | MEDICINE, RESEARCH & EXPERIMENTAL | microRNA26 | apoptosis | PHASE-II | CHEMOTHERAPY | TEMOZOLOMIDE | TRIAL | METASTATIC MELANOMA | DOSE-ESCALATION | NAIVE PATIENTS | IPILIMUMAB PLUS DACARBAZINE | cutaneous squamous cell carcinoma | INHIBITOR
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 916 - 926
Journal Article
Journal Article